Logo image
Back
AB0233 Remission according to RAPID3 (routine assessment of patient index data 3) in patients with rheumatoid arthritis: a cross-sectional study from routine care at 3 usa sites
Abstract   Peer reviewed

AB0233 Remission according to RAPID3 (routine assessment of patient index data 3) in patients with rheumatoid arthritis: a cross-sectional study from routine care at 3 usa sites

I Castrejon, M J Bergman, K A Gibson, Y Yazici, J A Block and T Pincus
Annals of the rheumatic diseases, v 76(Suppl 2), p1130
Jun 2017
DOI: https://doi.org/10.1136/annrheumdis-2017-eular.2749
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1136/annrheumdis-2017-eular.2749View
Published, Version of Record (VoR) Restricted

Abstract

BackgroundRAPID3 remission criteria provide similar results to DAS28 criteria, although less stringent compared to ACR/EULAR Boolean criteria. RAPID3 remission criteria are more feasible in routine care1 and have been reported at 25% in patients from France1 and 21% from Norway2.ObjectivesWe examined the proportion of patients in remission and 3 other severity categories according to RAPID3 at 3 sites at which MDHAQ is completed by all patients in routine care.MethodsAll patients seen at each rheumatology site complete an MDHAQ/RAPID3 at all visits in the waiting area as part of their routine care. The MDHAQ includes 0–10 scores for physical function, pain and patient global estimate, compiled into a 0–30 RAPID3, as well as scores for fatigue, RADAI self-report of painful joints, and demographic data. Physicians complete a global assessment (DOCGL) on a 0–10 visual analog scale (VAS). A random visit with complete questionnaire data for each RA patient from each site was included in the analyses. The proportion of patients in 4 RAPID3 categories, high severity (>12/30), moderate severity (6.1–12), low severity (3.1–6), and remission (≤3), was computed. MDHAQ demographic and clinical measures and DOCGL were compared in the 4 RAPID3 severity groups using chi-square and ANOVA tests.Results420 RA patients from the 3 sites were analyzed. Remission rates according to RAPID3 severity ranged from 23% to 26%, similar to reported rates from France and Norway. Low severity ranged from 7–24%, moderate severity from 23–29% and high severity from 21–46%. Age and sex were similar in the disease severity categories at the 3 sites (Table). Patients in the moderate and high severity groups at each site had higher scores for fatigue, RADAI self-reported joint pain, and DOCGL.Table 1.Mean (SD) for demographic and clinical characteristic of patients in remission versus other disease severity categories according to RAPID3 in each site. *p<0.001Remission (≤3)Low (3.1–6)Moderate (6.1–12)High (>12) Site 1 (N=137)32 (23.4%)11 (8%)31 (22.6%)63 (46%) Female, n (%)27 (84.4%)9 (81.8%)26 (83.9%)59 (93.6%) Age, yrs58.5 (16.9)57.9 (18.8)56.8 (17.5)55.6 (14.5) Fatigue (0–10)1.1 (1.5)2.3 (2.0)3.1 (2.1)6.6 (2.3)* Self-report RADAI (0–48)1.9 (2.9)5.0 (3.9)7.5 (5.6017.0 (9.2)* DOCGL (0–10)1.6 (1.2)3.7 (1.7)3.2 (1.4)5.3 (1.9)*Site 2 (N=144)37 (25.7%)35 (24.3%)42 (29.2%)30 (20.8%) Female, n (%)28 (75.7%)22 (62.9%)34 (80.9%)24 (80%) Age, yrs56.6 (16.9)62.0 (14.6)62.3 (14.7)62.5 (15.9) Fatigue (0–10)0.9 (1.0)2.7 (1.9)4.1 (2.4)5.6 (3.0)* Self-report RADAI (0–48)NANANANA DOCGL (0–10)0.9 (1.3)1.0 (1.0)1.7 (1.5)3.4 (2.7)*Site 3 (N=139)32 (23%)10 (7%)33 (23.7%)64 (46%) Female, n (%)23 (72%)9 (90%)20 (62%)50 (79%) Age, yrs44.4 (13.8)43.8 (17.0)50.3 (17.8)50.9 (15.0) Fatigue (0–10)0.4 (0.8)2.6 (2.7)4.1 (2.7)6.9 (2.9)* Self-report RADAI (0–48)1.3 (1.9)4.7 (4.2)5.7 (5.1)18.3 (12.2)* DOCGL (0–10)1.1 (1.1)3.2 (1.9)2.5 (1.2)3.2 (1.5)*ConclusionsSimilar RAPID3 remission rates were seen at 3 USA sites (about 24%), comparable to results from France and Norway.References Castrejon I, Dougados M, et al. J Rheumatol 2013, 40(4):386–393.Uhlig T, Lie E, et al. J Rheumatol 2016, 43(4):716–723. Disclosure of InterestI. Castrejon: None declared, M. Bergman: None declared, K. Gibson: None declared, Y. Yazici: None declared, J. Block: None declared, T. Pincus Shareholder of: Health Report Services, Inc

Metrics

8 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Rheumatology
Logo image